Olendalizumab - CAS 2210314-30-8

Olendalizumab (ALXN1007), a humanized IgG2-G4-κ antibody derived from mice, specifically targets Complement protein C5a with a binding affinity (K i) of 60 pM. This compound is designed to inhibit the complement inflammatory pathway. Additionally, olendalizumab is utilized in the research of complement-mediated disorders triggered by the coronavirus [1] [2].

Complement System

Immunology/Inflammation

2210276

-20°C

Ice Packs

Inhibitory Antibodies